Tacrolimus is a calcineurin inhibitor and potent immunosuppressive drug that is primarily used to prevent cellular rejection following organ transplantation. It is also used topically to treat severe atopic dermatitis, severe refractory uveitis following bone marrow transplants, and the skin disorder vitiligo. Tacrolimus is available in capsule, granules for oral suspension (to be combined with liquid), extended-release (long acting) capsule, and extended-release tablet for oral administration. Tacrolimus immediate-release formulations, in combination with other immunosuppressants, are approved for the prevention of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants. Tacrolimus extended-release formulations are approved for the prevention of organ rejection in adult and pediatric patients having kidney transplants when combined with other immunosuppressants, and may be used in patients who have been converted from immediate-release formulations.

Market Dynamics

The increasing product launch by the key players in the market is expected to drive the market growth over the forecast period. For instance, in June 2020, Sandoz, a Novartis division and a global leader in generic pharmaceuticals and biosimilars, announced the launch of once-daily generic tacrolimus capsules known as Dailiport in Germany, the U.K., The Netherlands, Finland, Sweden, Estonia, Latvia, and Slovakia, and as Conferoport in Italy and Spain.

Moreover, key companies in the market are focusing on inorganic growth strategies such as distribution of tacrolimus products, which is expected to drive the market growth over the forecast period. For instance, in January 2022, Mayne Pharma Group Limited, an Australia-based specialty pharmaceutical company announced that it had begun distribution of tacrolimus ointment, 0.1% in the U.S. Tacrolimus ointment is a generic version of PROTOPIC, indicated for the treatment of Atopic dermatitis.

Key features of the study:

• This report provides an in-depth analysis of the global tacrolimus market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global tacrolimus market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Novartis AG, Mylan N.V., Astellas Pharma Inc., Dr. Reddy's Laboratories Ltd., Pfizer Inc., Abbott, Senju Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Ltd., Lupin Limited, and Vibcare Pharma Pvt. Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global tacrolimus market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tacrolimus market

Detailed Segmentation:

• Global Tacrolimus Market, By Product Type:
  • Tacrolimus Capsules and Tablets
  • Tacrolimus Ointment 
  • Tacrolimus Injection 
  • Tacrolimus Granules 
• Global Tacrolimus Market, By Application:
  • Immunosuppression
  • Dermatitis
  • Others
• Global Tacrolimus Market, By End User:
  • Organ Transplant Centers
  • Hospitals 
  • Clinics
  • Others
• Global Tacrolimus Market, By Region:
  • North America
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Region/Country
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • Novartis AG
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Mylan N.V.
  • Astellas Pharma Inc.
  • Reddy's Laboratories Ltd.
  • Pfizer Inc.
  • Abbott
  • Senju Pharmaceutical Co. Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Limited
  • Vibcare Pharma Pvt. Ltd.

“*” marked represents similar segmentation in other categories in the respective section.